Autoimmune Diagnostics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 2.0 billion
Estimated Base Value
2035 Forecast
US$ 5.6 billion
Projected Market Value
CAGR 2026–2035
10.8%
Compound Annual Growth
Largest Segment
ELISA
Fastest Growing Segment
Chemiluminescence Immunoassays
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
28.5% market share
Key Players
Revvity
Emerging Players
Immunovia AB, ZEUS Scientific
Market Definition & Overview
The Autoimmune Diagnostics Market encompasses medical devices, instruments, reagents, and related services utilized for the detection, diagnosis, and monitoring of autoimmune diseases. This market includes technologies designed to identify specific autoantibodies, inflammatory biomarkers, and genetic predispositions associated with conditions like rheumatoid arthritis, lupus, celiac disease, and multiple sclerosis. It covers various diagnostic platforms such as immunoassays, molecular diagnostics, and flow cytometry employed in clinical laboratories, hospitals, and point-of-care settings to facilitate early diagnosis, disease stratification, and treatment efficacy assessment, ultimately improving patient outcomes.
Scope
- Global coverage across all major regions and emerging economies
- Focus on medical devices and in-vitro diagnostics specific to autoimmune diseases
- Analysis spanning a historical period, current year estimates, and a forecast period (e.g., 2023-2033)
Inclusions
- Immunoassay systems (ELISA, chemiluminescence, multiplexing platforms)
- Molecular diagnostic kits and instruments for autoimmune markers
- Point-of-care diagnostic devices for autoimmune conditions
- Reagents and consumables specifically for autoimmune testing
- Software and data analysis solutions for autoimmune diagnostic results
- Autoantibody tests (e.g., ANA, RF, anti-CCP, ANCA)
Exclusions
- Therapeutic drugs or biologics for autoimmune disease treatment
- General laboratory equipment not specific to autoimmune diagnostics
- Diagnostic imaging modalities (e.g., MRI, CT) not dedicated to autoimmune identification
- Research-use-only (RUO) products not cleared for clinical diagnostic application
- Clinical services beyond the diagnostic testing itself
Market Size Forecast
Executive Summary
• The Autoimmune Diagnostics market is valued at $2.0 Bn in 2025 and is forecast to reach $5.6 Bn by 2035, reflecting a robust CAGR of 10.8% as demand accelerates across every major segment and region over the ten-year outlook.
• ELISA leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 34.5%, while Emerging Areas is expanding the fastest at a 9.2% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 28.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Increasing consolidation among key players is intensifying competition, driving a strategic focus on integrated diagnostic platforms to secure market dominance and expand global reach, particularly in emerging economies.
• Technological advancements in multiplex assays and AI-powered diagnostics are significantly accelerating early disease detection and personalized treatment strategies, acting as critical growth catalysts across all major regions.
• Divergent global regulatory landscapes are profoundly influencing market entry barriers and product innovation, compelling manufacturers to adapt localized strategies for new autoimmune diagnostic solutions, impacting regional market access.
• Untapped potential in emerging markets necessitates localized product development and investment in diagnostic infrastructure, creating unique competitive advantages for agile companies adapting to diverse healthcare system requirements.
• Strategic investments in robust, localized supply chains and automated laboratory solutions are becoming paramount to mitigate geopolitical risks and meet escalating demand for efficient autoimmune diagnostic workflows globally.
• The market's future trajectory is heavily influenced by the adoption of decentralized point-of-care and non-invasive testing technologies, poised to significantly disrupt traditional centralized laboratory diagnostic models.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Autoimmune Diagnostics Market was valued at a significant $2.0 billion in the base year, establishing its considerable current economic footprint.
Impressive Growth Trajectory
The market is projected to expand rapidly, driven by an impressive compound annual growth rate (CAGR) of 10.8% during the forecast period.
Substantial Future Projection
By the forecast year, the market is expected to reach a substantial $5.6 billion, highlighting significant growth opportunities and potential.
Robust Market Expansion
The Autoimmune Diagnostics Market demonstrates robust overall expansion, growing from $2.0 billion to $5.6 billion at a remarkable CAGR of 10.8%.
North America Dominance
North America is anticipated to remain the leading regional segment, fueled by advanced healthcare infrastructure and a high prevalence of autoimmune disorders.
Technological Advancements Drive
A notable trend in the market is the continuous advancement in diagnostic technologies, including multiplexed assays and personalized testing, enhancing accuracy and efficiency.
Market Dynamics
Market Trends
- Increasing adoption of point-of-care (POC) diagnostic devices.
- Growing shift towards automation and high-throughput testing platforms.
- Focus on discovering novel biomarkers for earlier disease detection.
- Integration of personalized medicine approaches in diagnostics.
Growth Drivers
- Rising global prevalence of various autoimmune diseases.
- Aging population contributing to higher incidence of conditions.
- Increased awareness and early diagnosis initiatives.
- Continuous technological advancements in diagnostic methodologies.
Restraints
- High cost of advanced diagnostic tests limits widespread adoption.
- Lack of specific and sensitive biomarkers complicates early diagnosis.
- Stringent regulatory approval processes delay market entry for innovations.
- Limited awareness and access in developing regions pose significant challenges.
Opportunities
- Significant untapped potential in emerging economies for market expansion.
- Developing advanced diagnostics for very early disease detection.
- Growing demand for non-invasive and user-friendly testing methods.
- Leveraging AI and machine learning for improved diagnostic accuracy.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | ELISAImmunofluorescence AssaysChemiluminescence ImmunoassaysMultiplex ImmunoassaysWestern BlotRadioimmunoassaysMolecular Diagnostics |
| By Product | Reagents & KitsAnalyzers & InstrumentsSoftwareServices |
| By Application | Rheumatoid ArthritisSystemic Lupus ErythematosusHashimoto's ThyroiditisGraves' DiseaseCeliac DiseaseType 1 DiabetesInflammatory Bowel DiseaseMultiple Sclerosis |
| By End-User | Hospitals & ClinicsDiagnostic LaboratoriesAcademic & Research InstitutionsPhysician Office LaboratoriesAmbulatory Surgical Centers |
| By Automation Level | Fully Automated SystemsSemi-Automated SystemsManual Assays |
| By Sample Type | BloodUrineCerebrospinal FluidTissue BiopsySalivaOther Biological Fluids |
Regional Analysis
- North America leads the autoimmune diagnostics market due to its advanced healthcare infrastructure, high prevalence of autoimmune diseases, and significant R&D spending. The region benefits from strong patient awareness and the presence of major diagnostic companies, driving the adoption of sophisticated testing methods.
- The Asia-Pacific region is projected to be the fastest-growing market for autoimmune diagnostics. This growth is driven by improving healthcare infrastructure, rising disposable incomes, and increasing awareness about autoimmune diseases, alongside a large patient pool seeking early diagnosis.
- In Latin America and Middle East & Africa, there's an emerging trend towards adopting rapid, point-of-care (PoC) diagnostic tests for autoimmune diseases. This addresses limited access to centralized labs, improving diagnosis accessibility and speed in remote or underserved areas.
Asia Pacific
8.1% CAGR
$0.4 Bn
21.5% share
- Representing a rapidly growing market, Asia Pacific is fueled by increasing healthcare expenditure, improving medical infrastructure, and a large patient pool.
- Rising awareness about autoimmune diseases and the adoption of advanced diagnostics are key growth drivers.
North America
5.9% CAGR
$0.7 Bn
34.5% share
- This region dominates the market due to advanced healthcare infrastructure, high awareness, and significant R&D investments in diagnostic technologies.
- A high prevalence of autoimmune diseases further contributes to its leading market share.
Europe
5.5% CAGR
$0.6 Bn
27.8% share
- Europe holds a substantial market share, driven by well-established healthcare systems, an aging population, and robust government support for early disease diagnosis.
- Stringent regulatory frameworks also ensure the adoption of high-quality diagnostic solutions.
Latin America
7.5% CAGR
$0.1 Bn
7.2% share
- This region exhibits steady growth, propelled by expanding healthcare access, rising disposable incomes, and an increasing prevalence of autoimmune disorders.
- Investments in healthcare infrastructure and partnerships with international players are boosting market expansion.
Middle East & Africa
6.8% CAGR
$0.1 Bn
5% share
- A developing market experiencing growth due to increasing healthcare investments, improving diagnostic capabilities, and a rising incidence of autoimmune diseases.
- However, varied economic conditions and infrastructure development remain key challenges.
Emerging Areas
9.2% CAGR
$0.1 Bn
4% share
- Characterized by nascent but rapidly expanding healthcare markets, these regions are driven by increasing awareness, improving access to basic healthcare, and unmet diagnostic needs.
- Although currently small, they show significant growth potential from a low base.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.6 Bn | 7.2% | The largest market driven by high prevalence of autoimmune diseases, advanced healthcare infrastructure, and significant R&D investments in diagnostic technologies. |
| 2 | Brazil | $0.0 Bn | 9.5% | The largest market in South America, driven by a large population, increasing healthcare access, and a rising prevalence of autoimmune conditions. |
| 3 | Germany | $0.1 Bn | 6.8% | A leading European market with strong R&D capabilities, a highly advanced healthcare system, and rapid adoption of innovative autoimmune diagnostic tools. |
| 4 | China | $0.2 Bn | 11.5% | A rapidly expanding market fueled by its immense patient pool, substantial government investment in healthcare infrastructure, and rising disposable incomes driving demand for advanced diagnostics. |
| 5 | Saudi Arabia | $0.0 Bn | 10.0% | Characterized by significant government investment in healthcare, a rising prevalence of certain autoimmune diseases, and ambitious health transformation initiatives. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Revvity | 5.7% | Leverage its extensive portfolio in life sciences and diagnostics, particularly the EUROIMMUN brand, to offer comprehensive autoimmune testing solutions globally. | Formed from the diagnostics and life sciences segments of the former PerkinElmer, retaining strong expertise in specialized diagnostics. | Continues to integrate and expand the EUROIMMUN autoimmune diagnostics portfolio into its global life sciences and diagnostics offerings. | EUROIMMUN Analyzer IAnti-CCP ELISAAnti-MPO ELISA+1 |
| 2 | Werfen | 5.4% | Focus on highly specialized diagnostics solutions, particularly in hemostasis, critical care, and autoimmunity, through advanced instrumentation and reagents. | A leading global company in specialized diagnostics with strong brands like Instrumentation Laboratory and Inova Diagnostics. | Acquired Immucor, Inc. to significantly expand its portfolio into transfusion and transplant diagnostics. | NOVA ViewQUANTA-Lyser 120QUANTA Flash+1 |
| 3 | QuidelOrtho | 5.1% | Leverage a broad diagnostics portfolio, from rapid point-of-care to high-throughput lab solutions, to address diverse testing needs including autoimmune conditions. | Formed from the merger of Quidel Corporation and Ortho Clinical Diagnostics, creating a major global diagnostics player. | Focuses on integrating its diverse diagnostic technologies and expanding market reach for comprehensive testing solutions. | VITROS ECIQ Immunodiagnostic SystemORTHO Clinical Diagnostics ANA testsCeliac Disease Panel tests+1 |
| 4 | DiaSorin | 4.9% | Focus on the immunodiagnostics and molecular diagnostics markets with fully automated platforms and a broad menu of specialty tests, including autoimmune. | A global leader in immunodiagnostics, particularly known for its LIAISON platform and extensive specialty test menu. | The acquisition of Luminex Corporation significantly expanded its molecular diagnostics and multiplexing capabilities. | LIAISON XLLIAISON XSLIAISON ANA Screen+1 |
| 5 | bioMérieux | 4.6% | Provide integrated diagnostic solutions, from microbiology to immunoassays, to improve patient health outcomes, particularly in infectious diseases and specific autoimmune markers. | A global leader in in vitro diagnostics, with strong expertise in microbiology and specialized immunoassays. | Continues to expand its BioFire FilmArray portfolio for syndromic infectious disease testing and global adoption. | VIDASVITEK 2BioFire FilmArray+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Revvity, Werfen, QuidelOrtho, DiaSorin, bioMérieux, Bio-Rad Laboratories, QIAGEN, Grifols, Aesku Diagnostics, Immundiagnostik AG, Fujirebio, Trinity Biotech, DRG International, ALPCO, Omega Diagnostics, Medipan GmbH, Mikrogen GmbH, Novatec Immundiagnostica GmbH, Diamedix Corporation, GenWay Biotech, Inc.
The global Autoimmune Diagnostics market features a competitive landscape led by Revvity, Werfen, QuidelOrtho, DiaSorin, bioMérieux, and Bio-Rad Laboratories, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Revvity
Werfen
QuidelOrtho
DiaSorin
bioMérieux
Bio-Rad Laboratories
QIAGEN
Grifols
Aesku Diagnostics
Immundiagnostik AG
Fujirebio
Trinity Biotech
DRG International
ALPCO
Omega Diagnostics
Medipan GmbH
Mikrogen GmbH
Novatec Immundiagnostica GmbH
Diamedix Corporation
GenWay Biotech, Inc.
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
New AI-Powered Multiplex Assay Revolutionizes Early Autoimmune Disease Detection
A leading diagnostics firm launched an AI-powered multiplex assay capable of simultaneously detecting multiple autoimmune biomarkers with high sensitivity, promising earlier and more accurate diagnosis for complex conditions like lupus and rheumatoid arthritis. This innovation aims to enable timelier treatment interventions.
Global Diagnostics Leader Acquires Innovator in Autoimmune Biomarker Technology
A major medical device conglomerate announced the acquisition of a specialized autoimmune diagnostics company renowned for its proprietary early biomarker detection platform. The move is expected to expand the acquirer's portfolio and strengthen its position in the rapidly evolving autoimmune diagnostics market.
Strategic Partnership to Advance Companion Diagnostics for Novel Autoimmune Therapies
A prominent diagnostic company formed a strategic partnership with a biopharmaceutical giant to co-develop companion diagnostics for a new class of autoimmune disease therapies currently in late-stage clinical trials. This collaboration aims to personalize treatment by identifying patients most likely to respond to specific drugs.
Biotech Startup Secures $50M in Series B Funding for Advanced Autoimmune Diagnostics
A promising biotech startup focused on developing rapid, point-of-care diagnostic solutions for autoimmune diseases successfully closed a Series B funding round, raising $50 million. The investment will accelerate the commercialization of its innovative liquid biopsy platform and fuel further research.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $2.0 Bn |
| Market Size (Forecast) | $5.6 Bn |
| CAGR | 10.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 33 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included